ConforMIS, Inc. (NASDAQ:CFMS)‘s stock had its “hold” rating reaffirmed by research analysts at BTIG Research in a research note issued to investors on Sunday.

CFMS has been the subject of several other research reports. Canaccord Genuity set a $8.00 price target on ConforMIS and gave the company a “hold” rating in a research note on Thursday, May 11th. Zacks Investment Research raised ConforMIS from a “sell” rating to a “buy” rating and set a $4.75 price target for the company in a research note on Wednesday, July 12th. B. Riley reissued a “buy” rating and issued a $7.50 price target on shares of ConforMIS in a research note on Tuesday, May 16th. Finally, Oppenheimer Holdings, Inc. set a $9.00 price target on ConforMIS and gave the company a “buy” rating in a research note on Wednesday, May 10th. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $9.04.

ConforMIS (NASDAQ CFMS) traded up 0.67% on Friday, reaching $4.48. 14,972 shares of the company traded hands. The firm has a 50 day moving average price of $4.37 and a 200 day moving average price of $6.07. The stock’s market capitalization is $196.45 million. ConforMIS has a 52-week low of $3.79 and a 52-week high of $10.93.

ConforMIS (NASDAQ:CFMS) last announced its quarterly earnings results on Wednesday, May 10th. The medical instruments supplier reported ($0.40) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.36) by $0.04. The firm had revenue of $20.50 million during the quarter, compared to the consensus estimate of $18.48 million. ConforMIS had a negative net margin of 74.55% and a negative return on equity of 60.57%. The company’s quarterly revenue was up 1.0% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.37) EPS. Equities research analysts predict that ConforMIS will post ($1.43) EPS for the current year.

WARNING: “ConforMIS, Inc. (NASDAQ:CFMS) Rating Reiterated by BTIG Research” was first posted by Daily Political and is owned by of Daily Political. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://www.dailypolitical.com/2017/07/18/conformis-inc-nasdaqcfms-rating-reiterated-by-btig-research.html.

In related news, insider Daniel Steines sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, April 26th. The stock was sold at an average price of $5.54, for a total value of $27,700.00. Following the completion of the sale, the insider now directly owns 190,745 shares in the company, valued at approximately $1,056,727.30. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Bradley Langdale sold 6,722 shares of the business’s stock in a transaction that occurred on Tuesday, June 20th. The stock was sold at an average price of $4.30, for a total value of $28,904.60. Following the completion of the sale, the director now owns 26,533 shares of the company’s stock, valued at $114,091.90. The disclosure for this sale can be found here. 9.55% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Geode Capital Management LLC raised its position in shares of ConforMIS by 4.4% in the first quarter. Geode Capital Management LLC now owns 329,058 shares of the medical instruments supplier’s stock worth $1,717,000 after buying an additional 13,731 shares during the period. Wellington Management Group LLP raised its position in shares of ConforMIS by 2.4% in the first quarter. Wellington Management Group LLP now owns 5,644,206 shares of the medical instruments supplier’s stock worth $29,463,000 after buying an additional 132,211 shares during the last quarter. American International Group Inc. raised its position in shares of ConforMIS by 7.0% in the first quarter. American International Group Inc. now owns 22,009 shares of the medical instruments supplier’s stock worth $115,000 after buying an additional 1,448 shares during the last quarter. Marathon Capital Management purchased a new position in shares of ConforMIS during the first quarter worth approximately $1,052,000. Finally, Wells Fargo & Company MN raised its position in shares of ConforMIS by 1.8% in the first quarter. Wells Fargo & Company MN now owns 53,930 shares of the medical instruments supplier’s stock worth $282,000 after buying an additional 935 shares during the last quarter. Institutional investors own 39.31% of the company’s stock.

ConforMIS Company Profile

ConforMIS, Inc is a medical technology company. The Company uses its iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants, which are individually sized and shaped, to fit each patient’s anatomy. The Company’s iFit technology platform is applicable to various joints.

Analyst Recommendations for ConforMIS (NASDAQ:CFMS)

Receive News & Ratings for ConforMIS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConforMIS Inc. and related companies with MarketBeat.com's FREE daily email newsletter.